Investigating the effect of anti-reflux mucosal ablation (ARMA) in reducing the symptoms of esophageal reflux (GERD) in patients resistant to treatment with proton pump inhibitors (PPI)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046520N2

Enrollment

Registered

2023-10-03

Start date

2023-10-02

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease. Gastro-esophageal reflux disease without esophagitis

Interventions

Intervention 1: Intervention group: 24 patients aged 20 to 65 with reflux resistant to treatment with proton pump inhibitors, referring to Gastroenterology Clinic in Taleghani hospital, first complet

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 65 years At least one typical symptom of reflux more than twice a week Sliding hiatal hernia Hill grade minimum I and maximum III

Exclusion criteria

Exclusion criteria: Pregnancy Primary motility disorders of the esophagus Hiatal hernia sliding more than 3 cm Hill grade IV

Design outcomes

Primary

Measure	Time frame
The reduction of reflux symptoms in gastroesophageal reflux disease-related quality of life questionnaire (GERD-HRQL) and the frequency of gastroesophageal reflux disease symptoms (FSSG). Timepoint: Measurement of patients' symptoms based on questionnaires at the beginning of the study (before the start of the intervention) and 1 and 3 months after anti reflux mucosal ablation. Method of measurement: Gastroesophageal reflux disease-related quality of life questionnaire (GERD-HRQL), assessment of the frequency of gastroesophageal reflux disease symptoms (FSSG), upper endoscopy.	—

Measure

Time frame

The reduction of reflux symptoms in gastroesophageal reflux disease-related quality of life questionnaire (GERD-HRQL) and the frequency of gastroesophageal reflux disease symptoms (FSSG). Timepoint: Measurement of patients' symptoms based on questionnaires at the beginning of the study (before the start of the intervention) and 1 and 3 months after anti reflux mucosal ablation. Method of measurement: Gastroesophageal reflux disease-related quality of life questionnaire (GERD-HRQL), assessment of the frequency of gastroesophageal reflux disease symptoms (FSSG), upper endoscopy.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Moghtaderi

Shahid Beheshti University of Medical Sciences

Minamoghtaderi@yahoo.com+98 21 2243 2521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026